Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.49 |
| ▸ | POLA1 | P09884 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726994 | 0.85 | KCNH2 (0.55) | ALDH1A1KCNH2POLA1RXFP1 | |
| SCHEMBL6200011 | 0.85 | KCNH2 (0.53) | ALDH1A1KCNH2POLA1RXFP1TP53 | |
| SCHEMBL6770778 | 0.85 | KCNH2 (0.53) | ALDH1A1KCNH2POLA1RXFP1 | |
| SCHEMBL6202555 | 0.84 | RXFP1 (0.49) | ALDH1A1KCNH2POLA1RXFP1TP53 | |
| SCHEMBL6606941 | 0.84 | POLA1 (0.53) | ALDH1A1KCNH2POLA1RXFP1 | |
| SCHEMBL6200655 | 0.83 | KCNH2 (0.48) | ALDH1A1KCNH2POLA1RXFP1TP53 | |
| SCHEMBL6724134 | 0.82 | ALDH1A1 (0.46) | ALDH1A1RXFP1TP53 | |
| SCHEMBL6201283 | 0.81 | KCNH2 (0.54) | ALDH1A1KCNH2POLA1RXFP1 | |
| SCHEMBL6727162 | 0.80 | KCNH2 (0.49) | ALDH1A1KCNH2POLA1RXFP1 | |
| SCHEMBL6692811 | 0.79 | KCNH2 (0.51) | ALDH1A1KCNH2POLA1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029879-A1 | Heterocycle carboxamides as antiviral agents | ANDERSON DAVID JOHN (US) | 2004-02-12 | — | — | US | disclosed |
| US-6624159-B2 | Herpes virus | PHARMACIA & UPJOHN COMPANY | 2003-09-23 | — | — | US | disclosed |
| EP-1299387-A1 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020025959-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2002004445-A1 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029879-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | ALDH1A1 779/4885KCNH2 919/4885POLA1 267/4885 |
| US-20020025959-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | ALDH1A1 779/4885KCNH2 919/4885POLA1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.